Pelareorep shows promising HPV-targeted immune activity as Oncolytics Biotech advances cancer research
Oncolytics Biotech reports HPV-specific T-cell responses with pelareorep in anal cancer. See what the new immune findings mean for treatment.
Pharma & Biotech
Pharma & Biotech
Oncolytics says FDA opens a possible accelerated-approval route for pelareorep in RAS-mutant colorectal cancer
FDA written feedback supports a potential pivotal expansion of REO 033 using response rate and duration as an accelerated-approval strategy, but Oncolytics must first generate supportive randomized Part A data.
Pharma & Biotech
What Oncolytics Biotech, Inc.’s latest data reveals about overcoming MSS colorectal resistance
Explore how Oncolytics Biotech, Inc.’s pelareorep data could reshape MSS colorectal cancer care. Discover durability insights and what comes next.
Pharma & Biotech
What Oncolytics Biotech Inc.’s FDA meeting means for pelareorep commercialization
Can Oncolytics Biotech move pelareorep closer to approval in anal cancer? Read what the FDA meeting could change for clinicians and investors.
Pharma & Biotech
Why Oncolytics Biotech’s new GOBLET cohort 4 data matters for third-line anal cancer immunotherapy strategies
Find out why Oncolytics Biotech’s latest GOBLET cohort 4 data could reshape immunotherapy strategies for third-line anal cancer.